No treatment: total clinical fractures 20,401, fracture rate 67.1% and death rate after fracture of 6.1%. Total cost was €3,402.
Real-world persistence treatment: total clinical fractures 16,711, fracture rate of 60% and death rate after fracture of 4.9%. Total cost was €3,110.
Ideal persistence treatment: total clinical fractures 12,378, fracture rate of 49.1% and death rate after fracture of 3.4%. Total cost was €2,833.
The scenario of real-world persistence treatment dominated (more beneficial and less expensive than) no treatment and the ideal persistence treatment strategy dominated real-world persistence treatment.
Undiscounted costs did not alter the ranking of the strategies.
When the branded price was considered, the cost per fractured woman saved was €309 and premature death avoided was €2,251 with ideal persistence compared to real-world persistence treatment.
It was estimated that a 10% increase in persistence would save €58 per patient. Extrapolated to the French population a situation of ideal persistence would lead to savings of €30.5 million per year.